Inhibitory effects of icotinib combined with antiangiogenic drugs in human non-small cell lung cancer xenograft models are better than single target drugs.

Thorac Cancer · 2022 · PMC8758432 · PMID 34855286

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significancep > 0.05actually significant

Compared with the rh‐endostatin group alone, VEGFA level difference in the icotinib plus rh‐endostatin group did not reach statistical significance ( p > 0.05).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.